Groupe la Francaise bought a new stake in shares of Organon & Co. (NYSE:OGN – Free Report) in the second quarter, Holdings Channel.com reports. The fund bought 775,382 shares of the company’s stock, valued at approximately $10,499,000.
A number of other hedge funds have also recently made changes to their positions in OGN. Royal Bank of Canada lifted its holdings in Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after buying an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after acquiring an additional 801,307 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Organon & Co. by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after acquiring an additional 26,640 shares during the period. Focus Partners Wealth raised its stake in shares of Organon & Co. by 33.2% during the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after acquiring an additional 13,925 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Organon & Co. during the second quarter valued at approximately $107,000. 77.43% of the stock is currently owned by institutional investors.
Organon & Co. Stock Performance
OGN stock opened at $13.78 on Monday. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.78. The business has a 50-day moving average price of $13.61 and a 200 day moving average price of $11.34. The company has a market capitalization of $3.62 billion, a P/E ratio of 17.90, a PEG ratio of 1.28 and a beta of 1.52. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44.
Organon & Co. Dividend Announcement
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $11.40.
Organon & Co. Company Profile
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Further Reading
- Five stocks we like better than Organon & Co.
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
